NLRP3 and rheumatoid arthritis: Since the inflammatory responses in RA FLSs are mostly modulated by NF-κB and the NLRP3 inflammasome [90], the inhibition of NF-κB/NLRP3 pathways is therefore a potential therapeutic approach in RA management.